| Strategic International Session3（S）(JSGS・JSGE・JGES) |
| Fri. November 1st 14:00 - 17:00 Room 11: Portopia Hotel South Wing Topaz |
| Examination of our multimodal treatment for esophagogastric junction cancer | |||
| Takeshi Toyozumi1, Akira Nakano1, Hisahiro Matsubara1 | |||
| 1Department of Frontier Surgery, Graduate School of Medicine, Chiba University | |||
|
|||
|
|||
| [Background] Despite many studies on the treatment of esophagogastric junction cancer (EGJC), no consensus has been reached. [Purpose] To present our treatment policy for EGJC and share the treatment results. [Treatment Policy] Regardless of the histological type, we use a right thoracotomy approach and superior mediastinal dissection. Regarding perioperative treatment, we select a policy to that for esophageal cancer if the histology is squamous cell carcinoma (SCC), and for gastric cancer if the histology is adenocarcinoma (AC). [Materials and Methods] We will conduct a retrospective review for 94 patients with EGJC who underwent radical resection. [Results] SCC:AC was 44:50. The 3-year OS of SCC was 58.8%, AC was 71.7% (p=0.062). The recurrence rate was 20 cases (45.5%) in SCC and 19 cases (38.8%) in AC (p=0.646). The time of recurrence was later in AC (7.3 ±3.5 vs. 18.3 ±12.6 months, p<0.01). In AC, more than half (67.4%) had oligo-metastases-like recurrence with < ≤2 sites, which was more common than in SCC (35.0%) (p<0.01). For recurrence in AC, multimodal treatment including resection was selected in 5 cases (26.3%), and the prognosis was relatively good (3-year OS after recurrence: 60.0%). [Conclusion] Postoperative recurrence of esophagogastric junction AC took a long time to recur, and the number of recurrences tended to remain small. This suggests that active multimodal treatment, including resection, may contribute to favorable improvement. |
|||
|
Index Term 1: esophagogastric junction cancer Index Term 2: multimodal treatment |
|||
| Page Top | |||